NasdaqGM:HRMY
NasdaqGM:HRMYPharmaceuticals

Harmony Biosciences (HRMY) Is Up 7.8% After Earnings Jump and Revenue Guidance Reaffirmed – What's Changed

Harmony Biosciences Holdings recently reported second-quarter 2025 earnings, revealing net income of US$39.78 million versus US$11.59 million a year earlier and reaffirmed its full-year 2025 revenue guidance of US$820 million to US$860 million. This sharp improvement in earnings and maintained revenue outlook highlights the company’s operational momentum and management’s confidence in its ongoing business performance. With Harmony Biosciences delivering much higher profits and upholding its...
NYSE:GRND
NYSE:GRNDInteractive Media and Services

Grindr (GRND) Is Up 5.6% After Reporting Q2 Profitability and Strong Revenue Growth

Grindr Inc. recently announced its second quarter 2025 earnings results, reporting sales of US$104.22 million and a net income of US$16.64 million, marking a shift from a net loss for the same period last year. This turnaround to profitability, alongside strong year-over-year revenue growth, reflects the company’s improved operational performance and shifting financial trajectory. Now, we’ll explore how Grindr’s return to profitability could influence its investment narrative and future...
NasdaqGS:CORZ
NasdaqGS:CORZSoftware

How Core Scientific's (CORZ) Earnings Decline and Analyst Upgrades Are Shaping Its Investment Story

Core Scientific reported its second quarter 2025 earnings on August 8, showing revenue of US$78.63 million compared to US$141.1 million a year earlier, with a net loss of US$936.8 million and basic loss per share from continuing operations of US$0.04. Despite continued year-over-year declines in revenue and net losses, major Wall Street analysts recently upgraded or reaffirmed positive ratings for the company after the earnings report. We’ll examine how improved analyst sentiment, following...
NasdaqGS:DVAX
NasdaqGS:DVAXBiotechs

Is Dynavax Technologies' (DVAX) Raised HEPLISAV-B Guidance Reshaping Its Investment Narrative?

Earlier this month, Dynavax Technologies Corporation raised its full-year 2025 revenue guidance for HEPLISAV-B to a range of US$315 million to US$325 million and posted quarterly results showing second-quarter revenue climbed to US$95.44 million, with net income reaching US$18.72 million. The guidance increase reflects strong performance in the first half, while the earnings report highlights significant year-over-year growth in both revenue and profit margins for the company. To understand...
NYSE:VVX
NYSE:VVXAerospace & Defense

Why V2X (VVX) Is Up 21.2% After Follow-On Equity Offering Following Profitability Turnaround

Earlier this month, V2X, Inc. filed for a follow-on equity offering of 2,000,000 shares of common stock shortly after reporting a return to profitability in its second-quarter results and reaffirming its full-year revenue guidance. This sequence of events highlights how the company is taking advantage of renewed financial momentum to strengthen its balance sheet through equity financing. We'll explore how V2X’s follow-on equity offering, coming right after its profitability turnaround, may...
NYSE:CTEV
NYSE:CTEVHealthcare Services

Claritev (CTEV) Shifts Revenue Forecasts—Is Its Global Expansion Strategy Hitting an Inflection Point?

In the past week, Claritev Corporation reported second-quarter results showing higher sales at US$241.57 million and a sharply reduced net loss of US$62.64 million, while updating its full-year 2025 revenue guidance to between flat and 2% growth from 2024 levels. The company’s US$400 million universal shelf registration, covering a range of securities, adds financial flexibility to support potential future initiatives and growth plans. We will explore how Claritev’s improving financial...
NasdaqGM:VERA
NasdaqGM:VERABiotechs

Will Vera Therapeutics' (VERA) Major Equity Raise Reshape Its Resilience Amid Mounting Losses?

Vera Therapeutics recently reported a second quarter net loss of US$76.53 million, significantly higher than a year ago, and announced a US$200 million follow-on equity offering of Class A common stock. The concurrent disclosure of increased quarterly losses and a major capital raise highlights potential funding needs and ongoing operational pressures facing the company. We’ll examine how Vera Therapeutics’ expanded capital raise shapes its investment narrative amid growing financial...
NasdaqCM:BTBT
NasdaqCM:BTBTSoftware

Bit Digital (BTBT) Reports US$7M Sales Drop But Turns US$15M Profit

Bit Digital (BTBT) recently reported a significant 34% increase in share price over the last quarter, possibly influenced by key events such as its earnings announcement. The company noted a turnaround in net income to $14.87 million for the second quarter, a stark contrast from the previous year's losses. Although the broader market experienced a general upswing, Bit Digital's performance may have been impacted by its follow-on equity offerings and executive changes. Overall, while the...
NasdaqCM:QUBT
NasdaqCM:QUBTTech

Quantum Computing (QUBT): Sales Decline With US$36 Million Net Loss in Earnings Report

Quantum Computing (QUBT) announced considerable second-quarter financial setbacks, with sales dropping by 67% year-over-year and a net loss widening significantly. However, during the period, the company also marked important milestones, including securing a contract with the National Institute of Standards and Technology and shipping its first commercial entangled photon source. These developments coincided with a period where the Dow hit record highs, although the S&P 500 and Nasdaq...
NYSE:GLW
NYSE:GLWElectronic

Corning (GLW) Powers U.S. Solar Supply Chain with T1 Energy Partnership

Corning (GLW) recently announced a strategic commercial agreement with T1 Energy, focusing on the U.S. solar supply chain, which is aligned with national interests in energy self-sufficiency. Over the past quarter, Corning's stock price has risen by 36%, a move that likely benefited from multiple positive developments. The partnership with T1 Energy is significant, but other contributing events include the major expansion of Corning's partnership with Apple and their positive Q2 earnings...
NYSE:AON
NYSE:AONInsurance

Aon (AON) Faces Lawsuit Over Alleged Fraudulent CPI Product And Vesttoo Collapse

Aon (AON) has faced legal turmoil, with a lawsuit alleging fraudulent practices linked to its Collateral Protection Insurance product impacting the insurance sector and leading to Vesttoo's bankruptcy. This development coincides with Aon's exploration of selling Wealthspire Advisors and various executive appointments, such as Jo Ann Jenkins joining the Board. Meanwhile, the broader market saw mixed movements, with the Dow reaching new highs while other indices slipped slightly. Aon's 4% share...